Skip to main content

Table 3 Relapse free survival and metastasis free survival

From: Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma

 

Relapse free survival

Metastasis free survival

 

Five-year

P

Five-year

P

Total patients

34.4 ± 4.0

N/A

33.6 ± 3.9

N/A

Age

    

 ≤11(F), ≤12(M)

39.8 ± 14.2

 

26.6 ± 14.4

 

 12–14 (F), 13–15 (M)

37.3 ± 10.0

 

35.4 ± 9.6

 

15–39 (F), 16–39 (M)

33.3 ± 7.0

 

33.2 ± 6.7

 

 ≥40

37.5 ± 28.6

0.941

37.5 ± 28.6

0.952

Gender

    

 Male

32.1 ± 6.3

 

31.9 ± 5.9

 

 Female

41.9 ± 10.0

0.090

38.0 ± 9.7

0.053

Location

    

 Distal Femur

37.3 ± 7.7

 

32.4 ± 7.2

 

 Proximal Tibia

45.9 ± 9.9

 

41.8 ± 9.4

 

 Proximal humerus

25.0 ± 20.4

 

25.0 ± 20.4

 

 Proximal fibula

30.7 ± 17.1

 

46.0 ± 17.5

 

 Proximal Femur

25.0 ± 21.7

 

0

 

 Hip/Pelvic

0

 

0

 

 Others

0

0.454

57.1 ± 18.7

0.257

Pathological Fracture

    

 Yes

0

 

0

 

 No

37.1 ± 5.5

0.319

35.5 ± 5.2

0.386

Subtype

    

 Osteoblast

33.5 ± 5.7

 

31.9 ± 5.4

 

 Chondroblastic

29.3 ± 15.3

 

29.3 ± 15.3

 

 Fibroblastic

66.7 ± 19.2

 

83.3 ± 15.2

 

 Others

45.0 ± 32.2

0.257

33.8 ± 26.0

0.326

Chemotherapy

    

 Optimal Chemotherapy

49.0 ± 7.2

 

39.5 ± 6.7

 

 Suboptimal Chemotherapy

30.4 ± 6.0

0.009*

24.7 ± 6.1

0.005*

Local Recurrence

    

 Yes

 

13.7 ± 8.0

 

 No

40.3 ± 5.8

0.033*

Distal Metastasis

    

 Yes

21.1 ± 6.1

 

 

 No

50.1 ± 7.8

0.001*

  1. *, P <0.05; F, female; M, male.